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Background: The widespread use of drugs in prisons leads to avoidable deaths, poorer health 
and a poor living environment. The contribution of psychoactive prescription drugs to this 
problem has received little attention in prison policy and at individual prescriber level.  
Aims: To determine the extent of unsafe and inappropriate prescribing of psychoactive 
medications in one UK prison using a newly developed medicines optimisation framework. 
Method: A medicines optimisation framework was developed based on principles of good 
prescribing. It was initiated on the opening of a new prison - HMP Berwyn - in February 2017. 
During the study period, all prisoners at HMP Berwyn were transferred from other prisons. 
The safety and appropriateness of psychoactive medications were evaluated de novo on 
reception at HMP Berwyn and during follow up, using the medicines optimisation framework.  
Results: 1941 sentenced men arrived at HMP Berwyn between February 2017 and  November 
2018. Nearly one-third (634, 33%) were on a prescribed psychoactive medication. Seventy-
five percent of these (474/634) required a prescription change due to appropriateness or 
safety concerns. Nearly half (295, 46.5%) received changes at reception despite having 
already undergone medicines reconciliation at their previous prison. Forty-three percent 
(275/634) received changes at follow up, most commonly those who had no prior risks 
identified at reception. 
Conclusions Inappropriate and unsafe prescribing of psychoactive medications is occurring in 
prisons despite mandatory medication reviews. Ongoing monitoring is required to reduce the 
risk from these medications. A medicines optimisation framework such as this could be 
adopted across other prisons, worldwide, to help contribute to risk reduction from drug use 
in prisons. Appropriately modified, a similar framework might help reduce inappropriate and 
harmful prescribing in hospitals and in the community. 




Drug use has been described as the "biggest single destabilising factor" in prisons in England 
and Wales by Her Majesty’s Prison and Probation Service (HM Prison and Probation Service, 
2018) , directly contributing to adverse prisoner experiences and deaths. HMPPS Prisons’ 
Drugs Strategy emphasises that tackling this problem requires a co-ordinated effort to restrict 
supply, reduce demand, and build recovery (HM Prison and Probation Service, 2019). Publicity 
and funding focuses on restricting supply of drugs through illicit routes using enforcement 
strategies including random mandatory drug testing, increased sentences for positive drugs 
test, and searches for drug possession (HM Prison and Probation Service, 2018; Ministry of 
Justice, 2018, 2019a). There is much less emphasis by government on inappropriate and 
unsafe prescribing of psychoactive medications that can be misused or diverted, despite 
concern from the Prison and Probation Ombudsman (Moody, 2019).  
Any prescribed medication has the potential to be misused and cause harm. The Royal College 
of General Practitioners (RCGP) 2019 guidance Safer Prescribing in Prisons highlights that 
drugs with psychoactive effects have the highest risk of misuse, diversion, and dependence 
and that they should not be prescribed unless absolutely necessary (See supporting 
information – File 1) (Bicknell, Farmer, & Watson, 2019). Psychotropic medications are 
designed to have a psychological effect. Their prescription is four times higher for men in 
prison than in the general population, and invalid prescriptions based upon British National 
Formulary indication are common (Hassan et al., 2016). This does not take into account the 
strength of evidence for a diagnostic indication for the medication in the first place.  No data 
exist for the rates of prescribing for all psychoactive medications, including those that may be 
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used in combination with other medications to achieve a psychological effect, for example 
tramadol, a pain killer.   
Many male prisoners are polydrug users; in 2017/18 20.4% of all random mandatory drug 
tests in prisons were positive, most commonly for novel psychoactive substances (NPS) (60%), 
followed by cannabis, opiates, buprenorphine, and benzodiazepines (Ministry of Justice, 
2018). Taking psychoactive medications in combination with illicit drugs may offer temporary 
relief from prison life but carries a risk of overdose and death (Poole, Bailey, & Robinson, 
2019). Psychoactive medication is a tradable commodity; their distribution is associated with 
intimidation, bullying, violence, and debt (Bicknell et al., 2019).   
National Institute of Health and Care Excellence and RCGP guidance highlight the importance 
of medicines optimisation on reception and during stays in prison in order to mitigate the risk 
of adverse events (Bicknell et al., 2019; National Institute for Health and Care Excellence, 
2015, 2016). Although medicines optimisation should follow a multidisciplinary team 
approach, prescribers (usually a general medical practitioner/primary care physician working 
mainly or exclusively in prisons) have an individual responsibility to assess the 
appropriateness (justifiable diagnostic indication for the medication) and safety (risk of 
overdose and death) of medications. Minimal guidance exists on how clinicians should 
achieve this over time. Inappropriate and unsafe prescribing of psychoactive medications is 
not confined to prisons. Our group has suggested that transparent medicines management in 
prisons could offer better healthcare than is available in the community (Poole et al., 2019).  
We describe an evaluation of the medicines optimisation framework for psychoactive drugs 
that was implemented from the opening of HMP Berwyn, Wrexham, North Wales in February 
2017. During the study period, all receptions were sentenced men transferred from other 
6 
 
prisons. Our aim was to describe the extent of prescribing of concern for patients who had 
already been through reception medical processes in institutions where there was no 
structured programme to reduce it and preliminary outcomes of the medicines optimisation 
framework introduced.  
2. Methods 
2.1 Ethical considerations 
As this study uses an anonymised routinely collected dataset, the Betsi Cadwaldr University 
Health Board NHS research and development department recommend that the project is 
exempt from ethics approval. This project is registered with the Betsi Cadwaldr University 
Health Board Clinical Audit and Effectiveness office. 
2.2 Context 
The prison opened in February 2017. It is the largest in the UK and second largest in Europe, 
designed to hold up to 2106 category C male prisoners (HM Prison and Probation Service, 
2020). Category C prisoners are defined as “prisoners who cannot be trusted in open 
conditions but who do not have the resources and will to make a determined escape attempt” 
(Ministry of Justice, 2011). The stated aim for the prison is to foster a culture of empowerment 
and respect (HM Prison and Probation Service, 2020). By the end of March 2019, it held a 
total of 1283 men (Ministry of Justice, 2019b). Health services are provided by Betsi 
Cadwaladr University Health Board. Two general practitioners (GPs) provide primary care 
services and developed the medicines optimisation framework (MOF). This framework was 
initiated in collaboration with pharmacy services, substance misuse services, and with the 
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support of prison management when the prison first started to receive men. In this paper we 
report outcomes of the first 21 months of implementation.  
2.3 Intervention 
(i) At reception 
On reception, repeat prescriptions are checked by a nurse for any drug with psychoactive 
effects (See supporting information – File 2). When such prior prescription is reported, the 
man is asked to provide urine for a drug screening  test and the result is made available on 
the electronic health record. This includes primary care records (community and prison) and 
prison transfer records. The whole electronic health record is reviewed on the same day by a 
GP. Appropriateness of a medication is assessed by thorough scrutiny of the records to look 
for the diagnostic criteria which would legitimise use of a particular medication. Safety of a 
medication is assessed by reviewing alerts for intoxication recorded by health professionals 
at the previous prison, for example, suspected use of novel psychoactive substances. There 
are a number of possible outcomes from this review (Table 1, Figure 1): 
• Where medication is appropriate and there are no safety concerns, the prescription is 
continued. Medication, including controlled drugs, will be 'in possession' by default, meaning 
that each man will hold 28 days’ supply of his own medication in his cell, unless there are 
written instructions to the contrary. An ‘in possession risk assessment template’ is completed 
for each patient and then signed off by a senior pharmacist (Supporting information – File 3). 
This ensures that the patient is able to take the medication at the correct time as pharmacy 
dispensing times may not fit for certain drugs, for example, therapeutically justifiable 
hypnotics, and maintains patient autonomy. There are unannounced medication counts to 
check for stockpiling.   
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• Where there is no justifiable diagnostic indication for the medication (‘inappropriate 
medication’), it is not prescribed. A GP appointment is made for the next morning where 
further history, examination, and investigations are completed as necessary. If the medication 
is still deemed inappropriate, the reasons for discontinuation are discussed with the patient. 
A reducing regime is prescribed for drugs where withdrawal symptoms are likely. If the 
patient does not agree, discontinuation proceeds regardless. 
• Where a prescription for a sedative drug appears appropriate but there are safety 
concerns, it is not prescribed. An appointment is made for the next day to assess (history 
taking, examination, and investigation) to determine whether continuation is in the patient's 
best interest. Where the prescription is considered appropriate despite safety concerns, and 
there is no non-psychoactive alternative, the medication is dispensed by staff-observed single 
dosing (‘not in possession’). 
• The medications of all patients with a psychiatric diagnosis are reviewed by a prison 
based psychiatrist within a week. The psychiatrist will scrutinise prison and community 
records, order appropriate investigations (for example, electrocardiogram [ECG] for some 
anti-psychotic drugs), and a face to face review will be completed within 6 weeks. For these 
patients, medication is continued but ‘not in possession’ prior to psychiatric review. 
(ii) Follow up 
In cases where there was an appropriateness concern at reception (for example, further 
investigation of diagnosis needed), the patient will have a GP follow up appointment within 2 
weeks. Information that might raise a safety concern is shared with the GP via the electronic 
system, allowing them to re-evaluate the medication risk. Circumstances that would lead to 
an urgent clinical review include:  
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• Failure of a random mandatory drug test 
• Report of a patient found intoxicated 
• Incorrect count of ‘in possession’ medication 
• Positive urine drug screen from substance misuse services 
 
2.4 Service evaluation measures 
One of us (JL), who is a GP, searched the clinical database for men who had a urine drug screen 
between February 2017 and November2018. The clinical notes and results were reviewed to 
identify those who had one at reception solely as part of the Medicines Optimisation 
Framework. Basic demographic information including age and date of reception was 
collected. Changes to psychoactive medications at reception or on review were evaluated and 
attributed to appropriateness concerns, safety concerns, or both based upon of principles of 
good practice in prescribing (General Medical Council, 2013; National Institute for Health and 
Care Excellence, 2015). 
2.5 Analyses 
All data were transcribed into an Excel spreadsheet by JL. Data were checked by EB. Any 
inconsistencies in data were reported back to JL for review and amendment from the original 
electronic notes. After the data checking process there were no missing data. We undertook 
univariate linear regression analysis of the proportion of positive and negative urine drug 
screens per month from March 2017 to October 2018. February 2017 and November 2018 
data were excluded from this analysis due to incomplete data collection. The number of 
medication changes made at reception and follow up were analysed using Fisher’s exact test 
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(two-tailed).  All statistical calculations were performed using GraphPad Prism version 5 for 
Windows. Revised Standards for Quality Improvement Reporting Excellence (SQUIRE 2.0) 
were used to help write the manuscript (Ogrinc et al., 2016). 
 
3. Results 
3.1 Database search 
1941 men arrived at the prison during the study period (Supporting information – File 4).  No 
man was registered more than once. Seven hundred and ninety-five (41%) had a urine drug 
screen, most of these (634/795, 80%) solely because of the medicines optimisation 
framework. The median age of men on a prescribed psychoactive medication was 37.0 years 
(inter-quartile range [IQR] 31-44). 
3.2 Reception process 
Of 634 men asked for a urine sample for screening under the framework, ten refused to 
provide a sample. One hundred and sixty-six (26%) had a positive result for an illicit substance 
that was not accounted for by their prescription. Twenty-six (4%) had a negative urine drug 
screen for a medication that they were prescribed, suggesting diversion of the drug. 
There was a concern that men would obtain ‘clean’ urine as information about reception 
processes spread. We tested for this by completing linear regression analysis on screening 
results that had been completed at reception as part of the framework. There was an 
increasing trend in the proportion of tests that were negative for illicit substances and a 
decreasing trend in the proportion of tests that were positive for illicit substances (Supporting 
information – File 5). This was a weak trend (R2 = 0.1821, and R2 = 0.1749, respectively), and 
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neither line was significantly different from zero (P = 0.0665 and P = 0.0606, respectively), 
meaning that there is minimal statistical evidence to support the possibility that men were 
manipulating the system on arrival. 
Transfer records of 154 (24%) of the 634 urine screened men showed novel psychoactive 
substance use in the 3 months prior to the test. We found that, although evidence of 
intoxication was available in the notes, it had generally not been acted upon at the patient’s 
previous institution. Of those with evidence of using novel psychoactive substances, 41 had a 
positive urine drug screen at reception and one man refused this screen. 
Two hundred and ninety-five (46.5%) of the urine screened men had their psychoactive 
medication prescription changed at reception; the commonest reason for change was the 
combination of appropriateness and safety concerns (Table 2).  
3.3 Follow up 
Three hundred and fifty-six (56%) of the 634 men in the medicines optimisation framework 
had no follow up interventions after the initial reception process (Table 2). Reasons for this 
included the patient having an appropriate prescription with no subsequent safety concerns, 
or the patient leaving prison prior to follow up. Every patient has at least two medication 
reviews per year.  
Over 40% (278, 44%) of the men in the framework did have a follow up intervention and all 
but three required changes to their prescription (Table 2). Appropriateness concerns were 
addressed through face-to-face medication review. Of those requiring a face-to-face review, 
112 (41% of 272 recorded) had a medication change (Table 3). Safety concerns leading to a 
review were provoked by intoxication, incorrect medication count, or positive urine drug 
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screen. Medication changes on safety grounds were made for 106 (39% of 270 recorded), 84 
(32% of 263) and 31 (12% of 266) in respective groups (Table 3). Medication changes at follow 
up were more likely in those men who had had no medication change at reception. Of the 
339 men who had no change to their psychoactive medication at reception, 179 (53%)  
required changes at follow up due to safety concerns, appropriateness concerns, or both. Of 
the 295 on psychoactive medication at reception whose prescription was changed, just 96 
(32.5%) had a further change during the study period (P < 0.0001). 
Overall, including reception and follow up (follow up period dictated by patient either leaving 
the prison or the study ending), three-quarters of the men (474 of 634, 75%) had a 
psychoactive medication change due to appropriateness or safety concerns during the 21 
months of the study (Table 2). Indirect evidence of the success of the medicines optimisation 
framework was highlighted in a recent independent inspection of the prison where it was 
noted that 'very few prisoners were prescribed tradeable medicines' (HM Inspectorate of 
Prisons, 2019).   
 
4. Discussion 
About one third of all men arriving at HMP Berwyn were on psychoactive medication at the 
time of arrival. All had been transferred from other prisons. In almost half of these cases, the 
prescription was deemed inappropriate, unsafe, or both inappropriate and unsafe. This high 
proportion of prescriptions that needed to be changed is of concern given probable earlier 
opportunities to review medication. It is thus likely that appropriateness and safety of 
prescriptions for psychoactive drugs are not being considered adequately across the prison 
estate. It is recognised that prison prescribers may 'inherit' prescriptions commenced in the 
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community, that there are risks in not continuing some prescription and thus re-evaluation of 
need for them takes time. Further, withdrawal of a drug to which a prisoner feels attached or 
on which he is dependent is a significant task in itself. Nevertheless, another factor may be 
that the risk of harm arising from abuse of psychoactive medications (particularly for people 
with substance misuse histories) may be less apparent to doctors unfamiliar with prison 
environments (Bicknell, 2013). Prescribers working in prison should have training to provide 
them with skills to manage these risks appropriately. There is a precedent for this with opiate 
substitution programmes (Wright, French, & Allgar, 2014). Our prison GPs reported that they 
benefited from specialist training in substance misuse. All systems are open to manipulation, 
but we found no statistical evidence to suggest that men were using ‘clean’ urine on arrival. 
This must be monitored as it is a key point where the medicines optimisation  framework 
could be exploited.    
A nationwide study evaluating psychotropic medication use (including hypnotics, anxiolytics, 
antipsychotics, antidepressants, and CNS stimulants) in prison found that 35% of prescriptions 
had no accompanying record of an indication supported in the British National Formulary 
(Hassan et al., 2016). It is likely this is an underestimate of inappropriate prescribing as it does 
not include any scrutiny of the methods used to assess the strength of the evidence used to 
make the diagnosis and justify the medication, nor does it include all psychoactive 
medications. We found that about half of Berwyn’s men were on a psychoactive medication 
for a diagnosis without evidence of a disorder justifying the use of this medication, or a non-
essential medication that they were not taking. 
Perhaps one of the most important findings is the need for continuing risk evaluation after 
the reception process. Even in Berwyn, where there was high awareness of the risks and 
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formal adoption of the medicines optimisation framework, there were many men who had 
no prescription changes at reception but needed them later.  The prescription and taking of 
prescribed medication is a dynamic process and the task never complete. Having the 
framework helped identify any problems, such as evidence of intoxication, very quickly.  
Poly-drug misuse was common. Psychoactive prescription drugs interact with illicit drugs, 
increasing the risk of death. Novel psychoactive substances are particularly problematic 
because they are more difficult to detect, for example, they have no characteristic smell when 
smoked (Ministry of Justice, 2018; Ralphs, Williams, Askew, & Norton, 2017). Drugs known as 
synthetic cannabinoids can be addictive and ultra-potent. Unlike natural cannabis, their use 
has been implicated in drug related deaths in prisons (Moody, 2019; Ralphs et al., 2017). This 
underlines the need for clinicians to be aware of their possible use when assessing the safety 
of prescribing a psychoactive medication that is otherwise appropriately indicated.  
Control of access to potentially hazardous prescription drugs is an important element in 
prison substance misuse strategies, so prison doctors have a particularly important role in 
containing this. In principle, the situation in the community is no different. Clinicians working 
in all areas of healthcare should take ownership of the problem and its solutions. Patients 
may react negatively to having their medication stopped, but the primary objective is to 
promote health.  The prescriber must act in the patient’s best interest, which sometimes 
means saying “no”. This applies to all fields of medicine (Poole et al., 2019). 
A strength of this study is that is describes and evaluates implementation of a medicines 
optimisation framework for psychoactive medications. Bodies such as National Institute for 
Health and Care Excellence and RCGP have set out principles of how to avoid drug related 
morbidity and mortality (Bicknell et al., 2019; National Institute for Health and Care 
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Excellence, 2016) but, to the best of our knowledge, this is the first study to describe 
implementation of these principles.  
An essential element of this framework is that it is multidisciplinary, using expertise from GPs, 
pharmacists, substance misuse services, and psychiatrists, all of whom have had extensive 
experience in secure environments, as recommended by the Royal Pharmaceutical Society 
and others (Choudhry & Evans, 2014; Royal Pharmaceutical Society, 2017).   
Some limitations of this study must be considered. First, data were gathered retrospectively 
from the electronic notes by a single person (JL). Data were cleaned by a second person (EB) 
to identify inconsistencies to try to reduce the risk of transcription errors. It was not practical 
to have dual person data entry due to constraints on time and access to the prison database.  
Secondly, data collection was completed by one of the GPs delivering the intervention (JL). It 
is normal NHS practice for clinicians involved in service provision also to be involved in routine 
data collection for service evaluation, but does not allow for fully independent data collection.   
Thirdly, when considering the wider implications for prescribing in prisons we should bear in 
mind that the cohort studied at HMP Berwyn is not representative of the prison population 
as a whole. This population did not include any remand (pre-trial or pre-sentence) prisoners 
or those from establishments with lower levels of security, where psychoactive medication 
prescribing and those with substance misuse problems form a larger subsection of the 
population.  
Fourthly, information about the type of medication was not included in this routinely 
collected data set. The aim of the project was to evaluate the application of a set of principles 
to all medications with a psychoactive profile rather than to collect information about the 
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medications themselves, but we have included the list of medications classed as psychoactive 
for the purposes of evaluating the framework (Supporting information – file 2), and provided 
examples of appropriateness and safety concerns (Table 1).  
Fifthly, it was beyond the scope of this project to collect data about longer term impacts of 
the medicine optimisation framework. Anecdotally, at HMP Berwyn, it changes behaviour and 
encourages prisoners to take responsibility for their own health, both of which are key factors 
in mitigating institutionalisation. Also, it is likely to have a multifaceted health economic 
impact, through absolute reduction in number of prescribed items, reduced pressure on 
pharmacy and nursing teams, reduced pressure on security and fewer health crises. These are 
balanced by costs in staff times, disruption when men have medication discontinued, and 
potential complaints. We plan future research to answer some of these questions.  
If medicines optimisation frameworks are to be implemented across the whole prison estate, 
there must be greater recognition and support from HM Prison and Probation Service about 
the role of inappropriate and unsafe prescription medications in contributing to the supply 
and misuse of drugs in prison. Appropriately modified, a similar framework might help reduce 
inappropriate and harmful prescribing in hospitals and in the community. 
5. Conclusions 
We have described and evaluated the implementation of a framework for optimisation of 
psychoactive medication prescribing based upon principles of good prescribing. Our findings 
underscore the need for this, given the high proportion of men receiving psychoactive 
medication inappropriately or at some risk to their safety, and show that implementation is 
feasible. The framework could be adopted across other prisons in England and Wales to 
contribute to minimising risk from drug use in prisons. Many of the same principles might be 
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applied in wider clinical practice too, this also having a potential impact on prisoners as so 
many arrive on no longer appropriate prescriptions started in the wider community. Further 
research is required to understand the impact of such a framework on longer term health 
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  Examples 
Appropriateness 
concerns 
No formal diagnosis (based on nationally 
recognised guidelines) to justify prescription 
Urine drug screen  negative for prescribed 
medication suggesting it is not being taken 
Safety concerns Evidence of intoxication (e.g. NPS or alcohol) 
Evidence of illicit substance misuse 
Incorrect medication count suggesting diversion 
of medications or stockpiling 
Urine drug screen showing positive substances 
which are not prescribed 
Drug seeking behaviour 
Recent use of NPS 
Methadone dose too low for level of opiate 
tolerance evidenced by the presence of 
objective withdrawal 
Methadone dose too high for level of opiate 
tolerance evidenced by acute intoxication 
 


























Yes Continue Stop 
No Stop Stop 
 






Medication changed at reception 
Reason n 
Appropriateness and safety 194 (30.6%) 
Appropriateness only 56 (8.8%) 
Safety only 45 (7.1%) 
No change 339 (53.5%) 
Medication changed at follow up 
Reason n 
Appropriateness and safety 43 (6.8%) 
Appropriateness only 69 (10.9%) 
Safety only 163 (25.7%) 
No change 3 (0.5%) 
No follow up required 356 (56.2%) 
Medication change overall 
Reason n 
Appropriateness and safety 234 (36.9%) 
Appropriateness only 81 (12.8%) 
Safety only 159 (25.1%) 
No change 160 (25.2%) 
 





Face to face medication review Medication change 112 (41.2%) 
No medication change 160 (58.8%) 
Total 272 
Safety concerns 
Evidence of intoxication Medication change 106 (39.3%) 
No medication change 164 (60.7%) 
Total 270 
  
Medication count incorrect Medication change 84 (31.9%) 
No medication change 179 (68.1%) 
Total 263 
  
Subsequent urine drug screen Medication change 31 (11.7%) 
No medication change 235 (88.3%) 
Total 266 
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Medications with psychoactive effects at high risk of misuse, diversion, and dependence. 
Information collated from Royal College of General Practitioners ‘Safer Prescribing in 









Class of medication Example 






Certain Antiepileptics Clonazepam 
25 
 
Supplementary file 2 
Prescription medicines that indicate the need for a urine drug screen on arrival at HMP 
Berwyn 
Acamprosate; Alprazolam; Amisulpiride; Amitriptyline; Aripiprazole; Atomoxetine; Baclofen; 
Buprenorphine; Bupropion; Buspirone; Carbamazepine; Chlordiazepoxide; Chlorphenamine; 
Chlorpromazine; Citalopram; Clobazam; Clomipramine; Clonazepam; Clozapine; Co-
cododamol; Codeine; Co-dydramol; Cyclizine; Dexamfetamine; Diamorphine; Diazepam; 
Dihydrocodeine; Diphenhydramine; Disulfiram; Domperidone; Dosulepin; Duloxetine; 
Ethosuximide; Fentanyl; Flupentixol; Fluphenazine; Gabapentin; Haloperidol; 
Hydromorphone; Hydroxyzine; Hyoscine; Imipramine; Lacosomide; Lamotrigine; 
Levetiracetam; Levomepromazine; Lisdexamfetamine; Lithium; Lofexedine; Loperamide; 
Lorazepam; Melatonin; Methadone; Methylphenidate; Metoclopramide; Midazoplam; 
Mirtazapine; Modafanil; Morphine; Naltrexone; Nefopam; Nitrazepam; Nortriptyline; 
Olanzapine; Ondansetron; Oxazepam; Oxycodone; Paloperidone; Paroxetine; Perampenel; 
Pethidine; Phenelzine; Phenobarbital; Phenytoin; Pholcodine; Pregabalin; Prochlorperazine; 
Promazine; Promethazine; Pseudoephedrine; Quetiapine; Reboxetine; Risperidone; 
Rizatriptan; Sertraline; Sodium valproate; Sulpiride; Tapentadol; Temazepam; Topimirate; 
Tramadol; Trazadone; Valproic acid; Zolpidem; Zonisamide; Zopiclone; Zuclopenthixol. 





Supplementary file 3 
Information included in ‘In possession risk assessment template’ on HMP Berwyn 





• Mobile telephone 
• Client ID 






In possession risk assessment questionnaire and actions: (answer High/ Medium/ Low) 
1. Physical Health – Does the patient have the understanding of health problems 
likely to result in failure to take medication? 
2. Physical Health – Is the patient on a medication posing a significant and/or 
immediate risk if medication is omitted? 
3. Mental Health – Does the patient have capacity/ learning difficulties, problems 
reading, or any language issues? 
4. Mental Health – Does the patient have depression or risk of self harm or an open 
Assessment, Care in Custody and Teamwork (ACCT) plan? 
5. Mental Health – Does the patient have psychosis indicating a compliance risk? 
6. Security/ Safety – Has or is the patient demonstrating drug seeking behaviour? 
7. Security/ Safety – Has the patient had a positive mandatory drug test (MDT)? 
8. Security/ Safety – Has the patient tested positive for illicit substances? 
9. Security/ Safety – Does the patient have a history of trading medication or 
incorrect room in possession medication check ups? 
Action for prescriber: 
• Low physical or mental health risk – in possession medication for 28 days and 
repeat template for 6 issues 
• Medium physical or mental health risk – Not in possession for 28 days and 
request an appointment within that time period to reassess in possession status 
of patient 




• High security risk – In possession (7 or 28 days) and room medication check ups 







Supplementary file 4 
Flow diagram showing the process of identifying men with a prescription for a psychoactive 
medication on entering HMP Berwyn during the study period February 2017 - November 
























UDS not requested 
 
(n=1146) 
Men entering prison 
(n=1941) 
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